KalVista Pharmaceuticals (NASDAQ:KALV) Insider Paul Audhya Sells 2,685 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 2,685 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $26.78, for a total value of $71,904.30. Following the completion of the sale, the insider owned 147,499 shares of the company’s stock, valued at approximately $3,950,023.22. This trade represents a 1.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Up 0.1%

KALV opened at $26.81 on Wednesday. The business has a 50 day moving average price of $21.74 and a 200 day moving average price of $17.54. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.83 and a twelve month high of $26.85. The company has a debt-to-equity ratio of 8.18, a quick ratio of 5.10 and a current ratio of 5.17. The firm has a market cap of $1.43 billion, a P/E ratio of -7.75 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $39.17 million during the quarter, compared to analysts’ expectations of $39.03 million. Research analysts forecast that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on KALV shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. HC Wainwright lowered KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $37.00 to $27.00 in a report on Friday, May 1st. Citizens Jmp lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Wall Street Zen lowered KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 21st. Finally, Stifel Nicolaus upped their price target on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Three investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $30.60.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Bank of America Corp DE raised its stake in shares of KalVista Pharmaceuticals by 42.5% in the first quarter. Bank of America Corp DE now owns 555,628 shares of the specialty pharmaceutical company’s stock valued at $11,185,000 after purchasing an additional 165,815 shares in the last quarter. Royal Bank of Canada raised its stake in shares of KalVista Pharmaceuticals by 137.0% in the first quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,686 shares in the last quarter. Elmind Capital LP raised its stake in shares of KalVista Pharmaceuticals by 27.5% in the first quarter. Elmind Capital LP now owns 1,021,300 shares of the specialty pharmaceutical company’s stock valued at $20,559,000 after purchasing an additional 220,000 shares in the last quarter. Quantinno Capital Management LP raised its stake in shares of KalVista Pharmaceuticals by 11.3% in the first quarter. Quantinno Capital Management LP now owns 32,453 shares of the specialty pharmaceutical company’s stock valued at $653,000 after purchasing an additional 3,297 shares in the last quarter. Finally, Octagon Capital Advisors LP raised its stake in shares of KalVista Pharmaceuticals by 13.9% in the first quarter. Octagon Capital Advisors LP now owns 1,450,000 shares of the specialty pharmaceutical company’s stock valued at $29,188,000 after purchasing an additional 176,667 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.